Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing ...

As President Donald Trump vows to bridge the drug pricing gap between the U.S. and other developed countries with his “most ...

Pfizer Inc. (NYSE:PFE) is one of the best wide moat stocks to buy now. On June 9, Pfizer, along with other drug manufacturers ...

Pfizer and other drug companies have met with the Trump administration to discuss lowering U.S. drug prices but no ...

Pfizer (PFE) and other drugmakers met with the Trump administration to discuss lowering U.S. drug prices but no commitments have been made, Pfizer CEO Albert Bourla said on Monday at the Goldman Sachs ...

Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. | Pfizer's CEO ...

Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services ...

(Reuters) -Pfizer and other drug companies have met with the Trump administration to discuss lowering U.S. drug prices but no ...

Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 8:00 AM ETCompany ParticipantsAlbert Bourla - Chairman of ...

Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert Bourla, that landed in Pfizer’s cancer ...

U.S. lawmakers on Thursday asked Pfizer Inc for information on alleged comments by a former executive suggesting its research executives intentionally delayed clinical trial results of its COVID-19 ...

Pfizer and other drug companies have met with the Trump administration to discuss most-favored-nation pricing but no commitments have been made, Chief Executive Albert Bourla said on Monday at an ...